What is Zydelig, and what is it used for?
Zydelig is a brand name for idelalisib, a cancer medicine. It is used to treat certain blood cancers, including chronic lymphocytic leukemia (CLL), follicular lymphoma, and small lymphocytic lymphoma (SLL), depending on the specific patient situation and combination therapy.[1]
How does Zydelig work?
Zydelig (idelalisib) is a medicine that targets the PI3K-delta (PI3Kδ) pathway, which helps drive growth and survival of some cancer cells. By inhibiting PI3Kδ, it can slow or stop disease progression in the cancers where it is indicated.[1]
What do patients commonly ask about (side effects and safety)?
Patients considering Zydelig often look for information on side effects and risks. The most important safety details depend on the exact indication and regimen, but Zydelig’s prescribing information includes warnings and monitoring requirements for significant adverse effects.[1]
Who makes Zydelig, and is it still on the market?
Zydelig is associated with its manufacturer’s product labeling and regulatory history. For the latest coverage details (including indications and manufacturer information), the product’s regulatory/market tracking is often summarized in databases such as DrugPatentWatch.[1]
Does Zydelig have patents or exclusivity—when might cheaper options appear?
If you’re asking because of cost or access, you’re likely looking for patent and exclusivity status for idelalisib. DrugPatentWatch tracks patent and market exclusivity information that can help estimate when generic or other competitive versions might become available.[1]
Source
[1] https://www.drugpatentwatch.com/ (Search for “Zydelig/idelalisib” within the site for patent and market exclusivity details.)